Drugs that contain Raloxifene Hydrochloride
1. Evista patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5457117 | LILLY | Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride |
Jul, 2012
(11 years ago) | |
| USRE39049 | LILLY | Methods for inhibiting bone loss |
Jul, 2012
(11 years ago) | |
| US6906086 | LILLY | Methods for inhibiting bone loss |
Jul, 2012
(11 years ago) | |
| USRE38968 | LILLY | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
Jul, 2012
(11 years ago) | |
| US5393763 | LILLY | Methods for inhibiting bone loss |
Jul, 2012
(11 years ago) | |
| US5811120 | LILLY | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
Mar, 2014
(10 years ago) | |
| US5972383 | LILLY | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
Mar, 2014
(10 years ago) | |
| US5478847 | LILLY | Methods of use for inhibiting bone loss and lowering serum cholesterol |
Mar, 2014
(10 years ago) | |
| USRE39050 | LILLY | Methods of use for inhibiting bone loss and lowering serum cholesterol |
Mar, 2014
(10 years ago) | |
| US6458811 | LILLY | Benzothiophenes formulations containing same and methods |
Mar, 2017
(7 years ago) | |
| US6894064 | LILLY | Benzothiophenes, formulations containing same, and methods |
Mar, 2017
(7 years ago) | |
| US6797719 | LILLY | Benzothiophenes, formulations containing same, and methods |
Mar, 2017
(7 years ago) | |
| US8030330 | LILLY | Benzothiophenes, formulations containing same, and methods |
Mar, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Sep 13, 2014 |
Market Authorisation Date: 09 December, 1997
Treatment: Use for inhibiting bone resorption; Treatment of osteoporosis in postmenopausal women; Prevention of osteoporosis in postmenopausal women; Treatment or prevention of osteoporosis; Use for prevention o...
Dosage: TABLET;ORAL
How can I launch a generic of EVISTA before it's drug patent expiration?
More Information on Dosage
EVISTA family patents
